Apimeds Pharmaceuticals US (APUS) Interest Expenses (2023 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Interest Expenses of $278415.0 for Q4 2025, up 4318.58% on a QoQ basis from $6301.0 in Q3 2025, and up 157.12% year-over-year from $108281.0 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Interest Expenses (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Interest Expenses history runs 3 years deep, the most recent figure standing at $278415.0 for Q4 2025.
- Quarterly Interest Expenses rose 157.12% year-over-year to $278415.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $345802.0 (up 82.05% YoY) and the FY2025 annual result came in at $2.6 million, up 131.86% from the prior year.
- Interest Expenses was $278415.0 for Q4 2025 at Apimeds Pharmaceuticals US, up from $6301.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $800177.0 in Q4 2023 and bottomed at $6301.0 in Q3 2025.
- A 3-year average of $148436.6 and a median of $32638.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses slumped 86.47% — and 2025, when it jumped 157.12%.
- Apimeds Pharmaceuticals US's Interest Expenses stood at $800177.0 in 2023, then slumped by 86.47% to $108281.0 in 2024, then soared by 157.12% to $278415.0 in 2025.
- Business Quant data shows APUS's Interest Expenses at $278415.0 in Q4 2025, $6301.0 in Q3 2025, and $23054.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.77 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | 278,415.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 278,415.00 |
| Dec 31, 2025 | 278,415.00 |
| Sep 30, 2025 | 6,301.00 |
| Sep 30, 2025 | 6,301.00 |
| Jun 30, 2025 | 23,054.00 |
| Jun 30, 2025 | 23,054.00 |
| Mar 31, 2025 | 38,032.00 |
| Mar 31, 2025 | 38,032.00 |
| Dec 31, 2024 | 108,281.00 |
| Dec 31, 2024 | 108,281.00 |
| Sep 30, 2024 | 32,638.00 |
| Sep 30, 2024 | 32,638.00 |
| Jun 30, 2024 | 22,123.00 |
| Jun 30, 2024 | 22,123.00 |
| Mar 31, 2024 | 26,908.00 |
| Mar 31, 2024 | 26,908.00 |
| Dec 31, 2023 | 800,177.00 |
| Dec 31, 2023 | 800,177.00 |